Liposomal Formulation of a Melphalan Lipophilic Prodrug: Studies of Acute Toxicity, Tolerability, and Antitumor Efficacy.


Journal

Current drug delivery
ISSN: 1875-5704
Titre abrégé: Curr Drug Deliv
Pays: United Arab Emirates
ID NLM: 101208455

Informations de publication

Date de publication:
2020
Historique:
received: 01 07 2019
revised: 13 12 2019
accepted: 02 02 2020
pubmed: 15 2 2020
medline: 1 6 2021
entrez: 15 2 2020
Statut: ppublish

Résumé

Recently we developed a scalable scheme of synthesis of melphalan ester conjugate with 1,2-dioleoyl- Herein we compared this new convenient in use formulation of MlphDG with parent drug Alkeran Liposomes of approximately 100 nm in diameter, consisting of egg phosphatidylcholine, soybean phosphatidylinositol, and MlphDG, or placebo liposomes without the drug were produced by extrusion and lyophilized. Alkeran Liposomes showed approximately two times lower acute toxicity and better tolerability than Alkeran Lower toxicity of the liposomal formulation of MlphDG promises improved quality of life for cancer patients in need of treatment with melphalan. Presumably, the list of indications for melphalan therapy could be extended.

Sections du résumé

BACKGROUND BACKGROUND
Recently we developed a scalable scheme of synthesis of melphalan ester conjugate with 1,2-dioleoyl-
OBJECTIVE OBJECTIVE
Herein we compared this new convenient in use formulation of MlphDG with parent drug Alkeran
METHOD METHODS
Liposomes of approximately 100 nm in diameter, consisting of egg phosphatidylcholine, soybean phosphatidylinositol, and MlphDG, or placebo liposomes without the drug were produced by extrusion and lyophilized. Alkeran
RESULTS RESULTS
Liposomes showed approximately two times lower acute toxicity and better tolerability than Alkeran
CONCLUSION CONCLUSIONS
Lower toxicity of the liposomal formulation of MlphDG promises improved quality of life for cancer patients in need of treatment with melphalan. Presumably, the list of indications for melphalan therapy could be extended.

Identifiants

pubmed: 32056524
pii: CDD-EPUB-104505
doi: 10.2174/1567201817666200214105357
doi:

Substances chimiques

Antineoplastic Agents 0
Diglycerides 0
Liposomes 0
Prodrugs 0
Melphalan Q41OR9510P
diolein Z3MP1W91CW

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

312-323

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Daria Tretiakova (D)

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation.

Elena Svirshchevskaya (E)

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation.

Natalia Onishchenko (N)

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation.

Anna Alekseeva (A)

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation.

Ivan Boldyrev (I)

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation.

Roman Kamyshinsky (R)

National Research Center "Kurchatov Institute", Moscow, Russian Federation.

Alexey Natykan (A)

Drugs Technology Ltd., Khimki, Мoscow Region, Russian Federation.

Anton Lokhmotov (A)

Drugs Technology Ltd., Khimki, Мoscow Region, Russian Federation.

Diana Arantseva (D)

Drugs Technology Ltd., Khimki, Мoscow Region, Russian Federation.

Dmitry Shobolov (D)

Drugs Technology Ltd., Khimki, Мoscow Region, Russian Federation.

Elena Vodovozova (E)

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH